A phase 3 clinical trial demonstrated positive 3-year results for bilateral intravitreal injection of Lumevoq gene therapy, with statistically significant visual acuity improvements from baseline in both treated eyes.
Of the 98 participants in the randomized, double-masked, placebo-controlled REFLECT trial with vision loss due to Leber hereditary optic neuropathy (LHON) caused by a mutated ND4 mitochondrial gene, 48 were randomly assigned to receive Lumevoq (GS010; lenadogene nolparvovec) bilateral treatment while 50 received unilateral treatment and placebo, according to a press release from